Product image of Ibandronate Pharmacenter (Ibandronic Acid) supplied by GNH India

Ibandronate Pharmacenter

Active Ingredient:
Ibandronic Acid
Origin:
EU

Ibandronate Pharmacenter (Ibandronic Acid)

Ibandronic acid, the active ingredient in Ibandronate Pharmacenter, is a bisphosphonate presented as an oral tablet for oral use. It is indicated for osteoporosis in postmenopausal women, for fracture prevention in osteoporosis, and for Paget's disease of bone.
GNH India supplies Ibandronate Pharmacenter as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Pharmacenter Europe Kft.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Ibandronate Pharmacenter acts on bone remodeling pathways to treat several bone‑related disorders.

  • Osteoporosis in postmenopausal women: reduces the risk of vertebral and non‑vertebral fractures.
  • Prevention of fractures in osteoporosis: improves bone mineral density and lowers overall fracture incidence.
  • Paget's disease of bone: normalizes bone turnover and alleviates bone pain.

How It Works

  • Ibandronic acid binds selectively to hydroxyapatite crystals in bone, where it is taken up by osteoclasts during bone resorption. The drug inhibits farnesyl pyrophosphate synthase, disrupting the mevalonate pathway, which leads to osteoclast apoptosis and a net decrease in bone resorption, thereby stabilizing bone architecture.

Side Effects

Ibandronate Pharmacenter may cause a range of adverse reactions, from mild to serious.

Common Side Effects

  • Gastrointestinal upset: nausea, dyspepsia, or abdominal discomfort.
  • Musculoskeletal pain: transient bone, joint, or muscle aches.
  • Headache: mild to moderate intensity.
  • Esophageal irritation: mild soreness or heartburn.
  • Transient flu‑like symptoms: fever, chills, or myalgia.
  • Elevated serum calcium: mild hypercalcemia.

Serious or Rare Side Effects

  • Osteonecrosis of the jaw: exposed bone in the oral cavity.
  • Atypical femur fracture: low‑energy subtrochanteric fracture.
  • Severe esophagitis: ulceration or stricturing of the esophagus.
  • Acute phase reaction: severe fever, arthralgia, or rash.
  • Hypersensitivity: anaphylaxis or severe skin reactions.
  • Renal impairment: acute kidney injury or worsening of pre‑existing renal disease.

Precautions & Warnings

Before initiating therapy, clinicians should evaluate patient‑specific risk factors and follow safe handling practices.

  • Assess renal function: verify creatinine clearance is adequate before starting treatment.
  • Ensure adequate calcium/vitamin D: supplement to prevent hypocalcemia.
  • Take with water on an empty stomach: swallow with a full glass of water and remain upright for at least 30 minutes.
  • Avoid concomitant NSAIDs: reduces gastrointestinal irritation risk.
  • Review other bisphosphonate use: duplicate therapy is not recommended.
  • Store at room temperature: keep in the original pack, protect from moisture.

Avoid Interactions

Ibandronate Pharmacenter can interact with several drug classes, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid)

  • Concomitant oral bisphosphonates: additive bone effects may increase risk of oversuppression.
  • Calcium or multivitamin supplements taken within 2 hours: markedly reduces ibandronate absorption.
  • Antacids containing aluminum or magnesium: impair gastrointestinal uptake of the drug.
  • NSAIDs: increase risk of upper gastrointestinal irritation or ulceration.
  • Renally toxic agents (e.g., aminoglycosides): may exacerbate renal impairment.

Moderate Interactions (Monitor Closely)

  • Corticosteroids: may accelerate bone loss, counteracting therapeutic benefit.
  • Proton pump inhibitors: potential impact on calcium absorption and bone health.
  • Warfarin: possible increase in bleeding tendency.
  • Loop diuretics: alter calcium balance, requiring monitoring.
  • Hormone replacement therapy: additive anti‑resorptive effect may increase risk of rare bone complications.

Frequently Asked Questions

Ibandronate Pharmacenter, containing ibandronic acid, is prescribed for osteoporosis in postmenopausal women, for preventing fractures in patients with osteoporosis, and for managing Paget's disease of bone. These indications reflect its role as an anti‑resorptive agent that helps maintain bone strength.

Ibandronic acid binds to bone mineral surfaces and is taken up by active osteoclasts. It inhibits the enzyme farnesyl pyrophosphate synthase in the mevalonate pathway, leading to osteoclast apoptosis and a reduction in bone resorption, thereby stabilizing bone density.

The specific dose and dosing schedule for Ibandronate Pharmacenter are determined by the prescribing clinician based on the patient’s condition, renal function, and other individual factors. Patients should follow the prescriber’s instructions and not alter the regimen on their own.

The safety of ibandronic acid in pregnancy and lactation has not been established. It is generally advised to avoid use unless the potential benefit justifies the potential risk to the fetus or infant, and this decision should be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Ibandronate Pharmacenter is a potent bisphosphonate similar to alendronate or risedronate but is often administered less frequently (e.g., monthly). Its efficacy in reducing vertebral and non‑vertebral fractures is comparable, while its safety profile aligns with the class, featuring gastrointestinal and rare bone‑related risks.

Store Ibandronate Pharmacenter at room temperature, below 25 °C, in the original packaging. Protect the tablets from moisture and direct sunlight to maintain stability and potency throughout the shelf life.

The medication is taken orally as a tablet. Patients should swallow the tablet with a full glass of plain water on an empty stomach, at least 30 minutes before any food, beverage, or other medication, and remain upright for the same period to reduce esophageal irritation.

Serious risks, though uncommon, include osteonecrosis of the jaw, atypical femur fractures, severe esophagitis, and acute renal impairment. Patients should report persistent jaw pain, unusual thigh pain, severe gastrointestinal symptoms, or changes in kidney function promptly.

Ibandronate Pharmacenter is contraindicated in patients with known hypersensitivity to ibandronic acid or any tablet excipients, in those with severe renal impairment (creatinine clearance <30 mL/min), and in individuals unable to follow the required empty‑stomach administration protocol.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Ibandronic Acid

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT